Zentalis PharmaceuticalsZNTL
ZNTL
About: Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
Employees: 166
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
93% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 30
38% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 24
4% more funds holding
Funds holding: 136 [Q3] → 142 (+6) [Q4]
3% more call options, than puts
Call options by funds: $229K | Put options by funds: $222K
9.41% less ownership
Funds ownership: 99.8% [Q3] → 90.39% (-9.41%) [Q4]
25% less capital invested
Capital invested by funds: $261M [Q3] → $195M (-$66M) [Q4]
67% less funds holding in top 10
Funds holding in top 10: 3 [Q3] → 1 (-2) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$2.20
46%
upside
Avg. target
$5.55
268%
upside
High target
$10
562%
upside
4 analyst ratings
1 positive
25%
3 neutral
75%
0 negative
0%
Wedbush Robert Driscoll 4% 1-year accuracy 2 / 46 met price target | 165%upside $4 | Neutral Reiterated | 28 Mar 2025 |
HC Wainwright & Co. Andrew Fein 29% 1-year accuracy 102 / 354 met price target | 562%upside $10 | Buy Reiterated | 27 Mar 2025 |
Wells Fargo Derek Archila 48% 1-year accuracy 15 / 31 met price target | 297%upside $6 | Equal-Weight Maintained | 30 Jan 2025 |
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target | 46%upside $2.20 | Neutral Maintained | 28 Jan 2025 |
Financial journalist opinion
Based on 3 articles about ZNTL published over the past 30 days
Neutral
GlobeNewsWire
1 day ago
Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that an abstract has been accepted for poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3, 2025 in Chicago, IL.
Neutral
GlobeNewsWire
3 weeks ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on April 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 140,000 shares of the Company's common stock to three (3) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
4 weeks ago
Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates
Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC)
Neutral
GlobeNewsWire
4 weeks ago
Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025
One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in patients with high-grade serous ovarian cancer (HGSOC)
Neutral
GlobeNewsWire
1 month ago
Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients
Neutral
GlobeNewsWire
1 month ago
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on March 3, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 50,000 shares of the Company's common stock and 25,000 restricted stock units to one newly hired employee. The stock options and restricted stock units were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
Neutral
GlobeNewsWire
1 month ago
Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
Updated clinical data from ongoing DENALI clinical trial of azenosertib in patients with PROC Preclinical data of azenosertib demonstrating antitumor effects with microtubule inhibitor based ADCs SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced multiple presentations, including an oral presentation with updated clinical data from the ongoing Phase 2 DENALI clinical trial of azenosertib in patients with platinum-resistant ovarian cancer (PROC), at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting on Women's Cancer, to be held on March 14-17 in Seattle, Washington. Oral Presentation Abstract Title: Cyclin E1 is a Predictive Biomarker of Azenosertib Benefit in Platinum-Resistant Ovarian Cancer (PROC): Outcomes from Part 1b of the DENALI Study (GOG-3066) Presenter: Fiona Simpkins, M.D.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK CITY, NY / ACCESS Newswire / March 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK, NY / ACCESS Newswire / February 27, 2025 / NEW YORK, February 27, 2025 (ACCESSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc.("Zentalis" or the "Company") (NASDAQ:ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zentalis Pharmaceuticals, Inc. - ZNTL
NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zentalis Pharmaceuticals, Inc. ("Zentalis" or the "Company") (NASDAQ: ZNTL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
Charts implemented using Lightweight Charts™